Human papillomavirus and vaccination in cervical cancer

Taiwanese Journal of Obstetrics and Gynecology

Volumn 46, Issue 4, 2007, Pages 352-362

  Wang, Kung Liahng ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervarix; Cervical cancer; Gardasil; HPV; Human papillomavirus; Vaccines; Virus like particle vaccines

Indexed keywords

WART VIRUS VACCINE;

CANCER CONTROL; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; DNA EXTRACTION; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; PAPANICOLAOU TEST; REVIEW; SEXUAL TRANSMISSION; TAIWAN; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VERRUCA VULGARIS; VIRAL GENETICS; WART VIRUS;

EID: 38049016306     PISSN: 10284559     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1028-4559(08)60004-2     Document Type: Article

References (132)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Wang PD, Lin RS. Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 1996;62:344-52.
4. Lai MY, Chou P. Effectiveness of screening for cervical cancer in Taiwan. A case-control study. Zhonghua Yi Xue Za Zhi (Taipei) 1992;49:81-5. [In Chinese]
5. Bureau of Health Promotion, Department of Health, Taiwan. The Annual Decrease in Incidence and Mortality Rates of Cervical Cancer in Taiwan [in Chinese]. Available at: http://www.bhp.doh.gov.tw/asp/themeParkld=510/960305/ pdf/951116.pdf [Date accessed: 22 March 2007]
6. Renshaw AA, Mody DR, Lozano RL, Volk EE, Walsh MK, Davey DD, Birdsong GG. Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. Arch Pathol Lab Med 2004;128:153-7.
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
9. Nobbenhuis MA, Walboomers JM, Heimerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
10. Jacobs MV, Zielinski D, Meijer CJ, et al. A simplified and reliable HPV testing of archival Papanicolaou-stained cervical smears: application to cervical smears from cancer patients starting with cytologically normal smears. Br J Cancer 2000; 82:1421-6.
11. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94: 1406-14.
12. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003:3-13.
13. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26(4 Suppl):S2-7.
14. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6-10.
15. Centers for Disease Control and Prevention. Genital HPV infection factsheet. Available at: http://www.cdc.gov/std/HPV/STDFact-HPV.htm [Date accessed: 21 March 2007]
16. Bernard HU. Phylogeny and taxonomy of papillomaviruses. In: Campo MS, ed. Papillomavirus Research: From Natural History to Vaccines and Beyond. Norfolk, UK: Caister Academic Press, 2006:11-17.
17. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-27.
18. Sundberg JP, Van Ranst M, Burk RD, Jenson AB. The nonhuman (animal) papillomaviruses: host range, epitope conservation, and molecular diversity. In: Gross G, von Krogh G, eds. Human Papillomavirus Infections in Dermatovenereology. Boca Raton: CRC Press, 1997:47-68.
19. Sundberg JP, Van Ranst M, Montali R, et al. Feline papillomas and papillomaviruses. Vet Pathol 2000;37:1-10.
20. Tachezy R, Rector A, Havelkova M, et al. Avian papillomaviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus. BMC Microbiol 2002;2:19.
21. Orth G, Jablonska S, Breitburd F, Favre M, Croissant O. The human papillomaviruses. Bull Cancer 1978;65:151-64.
22. Howley PM. Papillomaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996:2045-76.
23. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987;61:962-7.
24. Bryan JT, Brown DR. Transmission of human papillomavirus type 11 infection by desquamated cornified cells. Virology 2001;281:35-42.
25. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, Schiller JT. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 1991;65: 4860-6.
26. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988;48:3780-6.
27. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89: 213-28.
28. Davey DD. Cervical cytology classification and the Bethesda System. Cancer J 2003;9:327-34.
29. Auvinen E, Crusius K, Steuer B, Alonso A. Human papillomavirus type 16 E5 protein. Int J Oncol 1997;11:1297-304.
30. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32(Suppl 1):S7-15.
31. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003:57-65.
32. The Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
33. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281: 1605-10.
34. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.
35. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
36. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
37. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180:1415-23.
38. Likes WM, Itano J. Human papillomavirus and cervical cancer: not just a sexually transmitted disease. Clin J Oncol Nurs 2003;7:271-6.
39. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005;32(Suppl 1):S1-6.
40. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
41. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
42. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
43. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
44. Chan PK, Mak KH, Cheung JLK, Tang NL, Chan DP, Lo KK, Cheng AF. Genotype spectrum of cervical human papillomavirus infection among sexually transmitted disease clinic patients in Hong Kong. J Med Virol 2002;68:273-7.
45. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
46. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005;37(6 Suppl):S3-9.
47. Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, Manos MM. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 1991;83:997-1003.
48. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CB. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-8.
49. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003;15:382-8.
50. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35-9.
51. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004;328:57-63.
52. Heard I. Cervical disease and cancer in HIV positive women. Recommendations for screening and diagnosis. Med Wieku Rozwoj 2003;7:479-85.
53. Branca M, Garbuglia AR, Benedetto A, et al. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. Int J STD AIDS 2003;14:417-25.
54. Conti M, Agarossi A, Parazzini F, Muggiasca ML, Boschini A, Negri E, Casolati E. HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusers. Gynecol Oncol 1993;49:344-8.
55. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
56. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191: 182-92.
57. Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005;16:528-37.
58. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-16.
59. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998;25:243-50.
60. Damasus-Awatai G, Freeman-Wang T. Human papilloma virus and cervical screening. Curr Opin Obstet Gynecol 2003; 15:473-7.
61. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis 2006;43:624-9.
62. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158: 486-94.
63. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
64. Moore MA, Tajima K. Cervical cancer in the Asian Pacific: epidemiology, screening and treatment. Asian Pac J Cancer Prev 2004;5:349-61.
65. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005;32(Suppl 1):S16-24.
66. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(Suppl 1):S1-15.
67. Centers for Disease Control and Prevention. Report to Congress: prevention of genital human papillomavirus infection. Available at: http://www.cdc.gov/std/HPV/2004HPVReport.pdf [Date accessed: 9 February 2005]
68. Christopher A. Hearing addresses condoms for HPV prevention. J Natl Cancer Inst 2004;96:985.
69. Frega A, Cenci M, Stentella P, Cipriano L, De loris A, Alderisio M, Vecchione A. Human papillomavirus in virgins and behaviour at risk. Cancer Lett 2003;194:21-4.
70. Frasier LD. Human papillomavirus infections in children. Pediatr Ann 1994;23:354-60.
71. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003;14:805-14.
72. Magnussen PK, Gyllensten UB. Cervical cancer risk: is there a genetic component? Mol Med Today 2000;6:145-8.
73. Magnussen PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
74. Kreider JW, Howett MK, Wolfe SA, Bartlett GL, Zaino RJ, Sedlacek T, Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985;317:639-41.
75. Kreider JW, Howett MK, Leure-Dupree AE, Zaino RJ, Weber JA. Laboratory production in vivo of infectious human papillomavirus type 11. J Virol 1987;61:590-3.
76. Bonnez W, Rose RC, Da Rin C, Borkhuis C, de Mesy Jensen KL, Reichman RC. Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model. Virology 1993;197:455-8.
77. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971-3.
78. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30.
79. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.
80. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001;61:1934-40.
81. Sharma D. Paper smear method for rapid HPV testing. Lancet Oncol 2002;3:454.
82. US Food and Drug Administration. New device approval: Digene Hybrid Capture 2 High-Risk HPV DNA Test - P890064 S009 A004. Available at: http://www.fda.gov/cdrh/mda/docs/p890064s009.html [Date accessed: 5 Aug 2007]
83. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32(Suppl 1):S43-51.
84. American Cancer Society. Cancer Facts and Figures 2004. Atlanta: American Cancer Society, 2004.
85. Cox JT. Management of cervical intraepithelial neoplasia. Lancet 1999;353:857-9.
86. Centers for Disease Control and Prevention. Incidence of Pap test abnormalities within 3 years of a normal Pap test - United States, 1991-1998. MMWR Morb Mortal Wkly Rep 2000;49:1001-3.
87. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyons, France: IARC Press, 2001.
88. International Agency for Research on Cancer Working Group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J (Clin Res Ed) 1996;293:659-64.
89. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001-5.
90. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003;127:959-68.
91. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
92. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-9.
93. Saslow D, Runowicz C, Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
94. Morantz C; American Cancer Society. ACS guidelines for early detection of cancer. Am Fam Physician 2004;69:2013.
95. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 66. Management of abnormal cervical cytology and histology. Obstet Gynecol 2005;106:645-64.
96. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 61. Human papillomavirus. Obstet Gynecol 2005;105:905-18.
97. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 45. Cervical cytology screening. Obstet Gynecol 2003;102:417-27.
98. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287: 2120-9.
99. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
100. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999; 43:65-8.
101. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention Vol 10: Cervix Cancer Screening. Lyon: IARC Press, 2005.
102. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-8.
103. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
104. Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities. Am J Obstet Gynecol 1999;181: 382-6.
105. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000;92:818-25.
106. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
107. Macaskill P, Walter SD, Irwig L, Franco EL. Assessing the gain in diagnostic performance when combining two diagnostic tests. Stat Med 2002;21:2527-46.
108. Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002;9:49-51.
109. Solomon D, Schiffman MH, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93: 293-9.
110. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
111. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
112. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
113. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95: 46-52.
114. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
115. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Am J Obstet Gynecol 2004;103:619-31.
116. Cox JT, Schiffman M, Solomon D; ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:1406-12.
117. Cox JT. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management. Obstet Gynecol Surv 2006;61(6 Suppl 1):S15-25.
118. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-7.
119. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12.
120. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J Virol 1993;67:1936-44.
121. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959-64.
122. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
123. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
124. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the use of quadrivalent HPV vaccine. Available at: http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf [Date accessed: 30 August 2006]
125. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging Infect Dis 2003; 9:37-48.
126. HPV vaccine fights cervical cancer. CA Cancer J Clin 2006;56:249-50.
127. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13:631-9.
128. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
129. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
130. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003;106:896-904.
131. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
132. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 2006;66:10229-32.